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Abstract
Objectives: To evaluate the effectiveness of lung cancer screening using low-dose computed tom-
ography for the general population, we conducted a retrospective cohort study of screening for
participants among Hitachi residents.
Materials and Methods: Citizens aged 50–74 who underwent low-dose computed tomography
screening at least once during 1998–2006 were defined as the computed tomography group, and
those who underwent X-ray screening at least once during the same period, but did not receive
low-dose computed tomography screening throughout the follow-up period, were defined as the
XP group. We investigated the lung cancer incidence rate, mortality rate and all-cause mortality
rate for both groups from the first lung cancer screening to the end of 2012.
Results: In the computed tomography group (17 935 residents; 9790 males and 8145 females), 273
cases of lung cancer (1.5%), 72 cases of lung cancer death (0.4%), and 885 cases of all-cause death
(4.9%) were observed. On the other hand, 164 cases (1.1%) of lung cancer, 80 cases (0.5%) of lung
cancer death and 1188 cases (7.6%) of all-cause death were observed in the XP group (15 548 resi-
dents; 6526 males and 9022 females). The hazard ratios of the computed tomography group to the
XP group adjusted for gender, age and smoking history were 1.23 for lung cancer incidence rate,
0.49 for lung cancer mortality rate and 0.57 for all-cause mortality rate. Non-smokers and light
smokers ( <30 pack-years) had a significantly lower lung cancer mortality (0.41 and 0.21,
respectively).
Conclusion: low-dose computed tomography screening for a population including non-smokers
and light smokers may be effective.
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Introduction
In Japan, 53 208 males and 21 170 females died of lung cancer in
2015, accounting for the highest cancer-related mortality rate
among cancers (1). The most important risk factor for lung cancer is
smoking. However, an increase in the incidence of lung cancer in
non-smokers (2) and increased risk of mortality from passive-
smoking-related lung cancer were recently reported (3).
Furthermore, in Asian countries, including Japan, the incidence of
lung cancer among non-smokers is higher than that in Europe/the
USA (4). Thus, in Japan, countermeasures for lung cancer in non-
smokers and light smokers are important.
According to the Prostate, Lung, Colorectal, and Ovarian
Cancer Screening Trial (PLCO) conducted in the USA, lung cancer
screening using chest X-ray did not reduce the lung cancer mortality
rate (5). On the other hand, in Japan, several case-control studies
reported a decrease in the lung cancer mortality rate (6), and chest
X-ray screening is conducted nationwide. However, a pooled ana-
lysis of these case-control studies in Japan revealed that the efficacy
of chest X-ray screening lasted only 1 year (6), and a more powerful
screening modality is awaited.
According to the results of the National Lung Screening Trial
(NLST), lung cancer screening using low-dose computed tomog-
raphy (LDCT screening) for heavy smokers reduced the lung cancer
mortality by 20% (7). In the USA, LDCT screening is covered by
Medicare (8), and in Europe, a statement was announced by a rele-
vant society (9). Therefore, LDCT screening for heavy smokers may
be increasingly applied in Western countries.
In Japan, LDCT screening has been employed since the 1990s
(10–12). However, different from other countries, examinees
included light smokers and non-smokers. As a result, a large number
of stage I lung cancers were detected, and the survival rate of LDCT
screening-detected lung cancer patients was high. As its effectiveness
for light smokers/non-smokers remains to be clarified, an assessment
study involving these subjects is necessary. Although Sagawa et al.
started a randomized controlled trial (RCT) for non-smokers and
light smokers to investigate the effectiveness of LDCT screening
(13), over 10 years are needed for the results. As LDCT screening
has been performed for many years in some areas of Japan, an
effectiveness assessment study using previous data on LDCT screen-
ing should be conducted.
In Hitachi city (Ibaraki Prefecture, Japan), LDCT screening for
people aged ≥50 years was introduced regardless of smoking status
for employees, retired persons and their spouses in 1998, and for
community dwellers or as a part of comprehensive health checkups
in 2001. It was estimated in 2006 that ≥30% of targeted residents
had undergone LDCT screening at least once by 2006. We previ-
ously conducted a chronological study to examine the lung cancer
mortality rate in residents aged 50−75 years in Hitachi city and
reported a 24% decrease in the lung cancer mortality rate 4−8 years
after the introduction of LDCT screening in comparison with that
for the Japanese population (14), but this chronological study had
several limitations. Thus, the aim of this retrospective cohort study
was to compare the mortality rate of those who underwent at least
one LDCT screening with that of those who underwent chest X-ray
screening.
Materials and methods
This study was primarily conducted in Hitachi city. Previous studies
have reported the methods and results of LDCT screening in the
Hitachi area (12,14,15). Briefly, LDCT screening was started for
employees aged 50–69 years, those who had retired, and their
spouses (Hitachi Health Care Center, Hitachi, Ltd.) in 1998. In
2001, it was successively introduced for residents aged ≥50 years as
a regional cancer screening (Hitachi Medical Center) and for exami-
nees aged ≥50 years during comprehensive health checkups (Hitachi
General Health Center). At these institutions, screening was per-
formed for males and females regardless of smoking status, i.e. non-
smokers were included. We initially established follow-up principles
for the management of detected pulmonary nodules, and the positive
test rate on LDCT screening was maintained at a low value. The
positive test rates on the first and repeat LDCT screening were 6.8
and 2.7%, respectively (12). A total of 98 264 LDCT scans were
performed for residents in Hitachi city between 1998 and 2012
(occupational setting: 50 483, regional setting: 34 723 and compre-
hensive health checkups: 13 058). On the other hand, annual chest
X-ray screening was recommended for all residents aged ≥40 years
in Hitachi city regardless of gender or smoking status, and sputum
cytology was additionally conducted for heavy smokers (≥30 pack-
years). The positive test rate ranged from 1.6 to 2.6%. We were
unable to obtain data for chest X-ray screening before 2000.
In this study, the ‘CT group’ was defined as residents who had
undergone LDCT screening at least once between 1998 and 2006
and were aged 50–74 years at the first LDCT screening. The obser-
vation period began on the day of the first LDCT screening between
1998 and 2006. On the other hand, the ‘XP group’ was defined as
residents who had undergone chest X-ray screening at least once
between 2001 and 2006 and were aged 50–74 years at the first
screening. However, there was an exclusion criterion for the XP
group, i.e. ‘those who had undergone LDCT screening at least once
during the entire study period (1998–2012)’ were excluded from the
study because the influence of LDCT screening was regarded as
extremely marked even in the follow-up period, and such residents
were not considered for the XP group. The observation period for
the XP group also began on the day of the first chest X-ray screen-
ing between 2001 and 2006.
The process of data accumulation is described in the following
(Fig. 1). The age at the first screening was defined as the age of the
subject in this study. The total number of subjects was 38 139
(CT group: 18 857 subjects, XP group: 19 282 subjects). Excluding
4593 who were aged ≥75 years, 28 diagnosed with lung cancer
before registration, and 35 who underwent screening after moving,
33 483 subjects (CT group: 17 935, XP group: 15 548) were finally
analyzed.
We gathered death, cause of death and lung cancer incidence
data until the end of 2012 from the Basic Resident Register of
Hitachi city, regional cancer registration of Ibaraki Prefecture, and
75 years or older (n = 4,593) excluded
74 years or younger (50 to 74 years)
n = 33,546 (CT group 17,956 subjects, XP group 15,590 subjects)
Registered (baseline screening) by 2006 
n = 38,139 (CT group 18,857 subjects, XP group 19,282 subjects)
Lung cancer incidence, deaths, and
all-cause deaths by 2012 were evaluated.
n = 33,483 (CT group 17,935 subjects, XP group 15,548 subjects)
Participants who had lung cancer before the
registration period (n = 28) or were screened
after moving (n = 35) were excluded. 
Figure 1. Data collection process.
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vital statistics reported by the Ministry of Health, Labour and
Welfare. The observation period was from the day of the first CT/
XP screening defined above to the day of event. In subjects without
events, the final day of follow-up was set as 31 December 2012.
When subjects moved to other areas during the follow-up period,
follow-up was completed the day of moving. Even if they returned,
follow-up was not resumed.
Regarding the pack-years of the subjects, we used the self-
reported value on the day of the first screening. The pack-years
values were classified into four categories: ‘0’, ‘0 < and < 30’, ‘30≤
and <50’ and ‘≥50’. For some subjects, a pack-years value of <30
was reported. We analyzed several scenarios for male with unknown
pack-years category or unknown smoking history (pack-years 1/2,
PYC1−4). Women with unknown pack-years category or smoking
history data were considered to be non-smoking. Based on the
smoking history of complete cases, we considered the pack-years 1
(PYC1) scenario, which assumed men with an unknown smoking
frequency or smoking history to be in the ‘0< and 30’ pack-years
category, to be the most realistic. Detailed methods and results of
analysis based on multiple scenarios are shown in the supplement.
The hazard ratios of LDCT screening for lung cancer incidence,
lung cancer mortality and all-cause mortality in subgroups classified
by gender/age/pack-years were calculated. In addition, we carried
out the complete case analysis on sensitivity analysis.
Statistical analysis was carried out using R software for
Windows (v.3.2.2; R Foundation for Statistical Computing) and the
survival package. The baseline characteristics for the CT group and
XP group were compared using the Student’s t-test for continuous
variables and Fisher’s exact test for categorical variables. For the
lung cancer incidence rate, lung cancer mortality rate and all-cause
mortality rate of the CT group and XP group, the hazard ratios and
their 95% confidence intervals were estimated with multivariate
Cox proportional hazards models adjusted for gender, age and
pack-years. A P value of 0.05 was regarded as significant.
The study was approved by the ethics review board of the hos-
pital administration headquarters, Hitachi Ltd. (No. 2013–46).
Results
The characteristics of the subjects are shown in Table 1. The CT
group consisted of 9790 males and 8145 females, and the XP group
consisted of 6526 males and 9022 females. The gender composition
of the two groups was significantly different. The mean age in the CT
group was significantly younger than that in the XP group. In the CT
group, the proportion of smokers among both males and females was
significantly higher than that in the XP group. The mean screening
cycles between 1998 and 2006 for males and females in the CT group
were 3.0 ± 2.3 times and 2.0 ± 1.5 times, respectively.
The distribution of pack-years is also shown in Table 1. For males,
‘0< and <30’ (pack-years 1) or ‘0’ (pack-years 2) was adopted as an
alternative category when only ‘a pack-years value of <30’ was
obtained. For 994 subjects (CT group: 389, XP group: 605) for whom
the pack-years value was not available (2.97% of all subjects), analyses
were conducted using the alternative pack-years category with the four
scenarios (PYC1−4) described in the supplement.
The follow-up period, number of lung cancer cases diagnosed,
number of lung cancer deaths, number of cancer deaths excluding
lung cancer and number of all-cause deaths excluding cancer in each
group are shown in Table 2. In the CT group, the mean follow-up
period was 9.85 ± 2.71 years, whereas it was 8.65 ± 2.09 years in
the XP group. In the CT group, 273 subjects developed lung cancer,
72 died of lung cancer, 404 died of cancer other than lung cancer and
409 died from other cause. On the other hand, 164 subjects devel-
oped lung cancer, 80 died of lung cancer, 516 died of cancer other
than lung cancer and 592 died from other cause in the XP group.
The cumulative incidence rate of lung cancer, lung cancer mor-
tality rate and all-cause mortality rate in each group are shown in
Table 1. The characteristics of the subjects
Male Female Total
CT group XP group P CT group XP group P CT group XP group P
Number of subjects 9790 6526 8145 9022 17 935 15 548
Mean age (SD) 58.3 (6.9) 62.0 (7.3) <0.001 60.1 (6.6) 61.2 (7.5) <0.001 59.1 (6.8) 61.6 (7.4) <0.001
Age group (%) <0.001 <0.001 <0.001
50–55 3882 (39.6) 1499 (23.0) 2372 (29.1) 2470 (27.4) 6254 (34.8) 3969 (25.5)
56–63 3355 (34.3) 1910 (29.3) 3041 (37.4) 2702 (29.9) 6396 (35.7) 4612 (29.7)
64–74 2553 (26.1) 3117 (47.7) 2732 (33.5) 3850 (42.7) 5285 (29.5) 6967 (44.8)
Smoking history (%) <0.001 <0.001 <0.001
Never 2414 (24.7) 1962 (30.1) 7337 (90.1) 8358 (92.7) 9751 (54.4) 10 320 (66.3)
Past 1916 (19.6) 1373 (21.0) 49 (0.6) 147 (1.6) 1965 (11.0) 1520 (9.8)
Current 5213 (53.2) 2830 (43.4) 623 (7.6) 288 (3.2) 5836 (32.5) 3118 (20.1)
Unknown 247 (2.5) 361 (5.5) 136 (1.7) 229 (2.5) 383 (2.1) 590 (3.8)
Pack-years 1 (%) <0.001 <0.001 <0.001
0 2414 (24.7) 1963 (30.1) 7338 (90.0) 8358 (92.7) 9752 (54.3) 10 321 (66.4)
0< and <30 3649 (37.2) 3097 (47.4) 504 (6.2) 298 (3.3) 4153 (23.2) 3395 (21.8)
30≤ and <50 2740 (28.0) 810 (12.4) 137 (1.7) 121 (1.3) 2877 (16.0) 931 (6.0)
50≤ 735 (7.5) 284 (4.4) 29 (0.4) 12 (0.1) 764 (4.3) 296 (1.9)
Unknown 252 (2.6) 372 (5.7) 137 (1.7) 233 (2.6) 389 (2.2) 605 (3.9)
Pack-years 2 (%) <0.001 <0.001 <0.001
0 2461 (25.1) 3345 (51.2) 7338 (90.0) 8358 (92.7) 9799 (54.6) 11 703 (75.3)
0< and <30 3602 (36.8) 1715 (26.3) 504 (6.2) 298 (3.3) 4106 (22.9) 2013 (12.9)
30≤ and <50 2740 (28.0) 810 (12.4) 137 (1.7) 121 (1.3) 2877 (16.0) 931 (6.0)
50≤ 735 (7.5) 284 (4.4) 29 (0.4) 12 (0.1) 764 (4.3) 296 (1.9)
Unknown 252 (2.6) 372 (5.7) 137 (1.7) 233 (2.6) 389 (2.2) 605 (3.9)
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Fig. 2. The cumulative incidence rate of lung cancer in the CT group
was higher than that in the XP group during the entire follow-up
period. A large number of lung cancer lesions were detected in the
CT group within 2 years after the first screening, causing a marked
difference between the two groups. Subsequently, the incidence rate
of lung cancer increased in the XP group 5−7 years after the first
screening, reducing the difference between the two curves. The two
groups then exhibited a similar increase (Fig. 2a).
There was no marked difference in the cumulative lung cancer
mortality rate (Fig. 2b) between the two groups within 2 years after
the first screening. Subsequently, there was a decrease in the lung
cancer mortality rate in the CT group after 3−4 years, and then
there was a marked decrease 5−8 years after the first screening. On
the other hand, the cumulative all-cause mortality rate in the CT
group was lower than that in the XP group throughout the follow-
up period, including during the first year (Fig. 2c). The slope of the
curve was constant and was not affected by the interval from the
first screening, differing from the cumulative incidence rate and lung
cancer mortality rate.
The hazard ratios calculated by multivariate analysis adjusted
for gender/age/pack-years in the ‘PYC1’ scenario of ‘pack-years 1’,
which may be the most realistic, are shown in Table 3. The adjusted
hazard ratios for the lung cancer incidence rate, lung cancer mortal-
ity rate and all-cause mortality rate in the CT group compared with
those in the XP group were 1.23 (95% confidence interval:
1.00–1.51), 0.49 (0.34–0.70) and 0.57 (0.52–0.62), respectively. In
the CT group, the lung cancer incidence rate was significantly higher
than that in the XP group, whereas the lung cancer mortality rate
Table 2. Follow-up period, lung cancer cases, deaths and all-cause deaths in each group
Male Female Total
CT group XP group P CT group XP group P CT group XP group P
Number of subjects 9790 6526 8145 9022 17 935 15 548
Mean follow-up days (SD) 3783 (1 054) 3201 (863) <0.001 3367 (851) 3 129 (681) <0.001 3594 (989) 3159 (763) <0.001
Number of lung cancer cases diagnosed
(%)
169 (1.7) 111 (1.7) 0.951 104 (1.3) 53 (0.6) <0.001 273 (1.5) 164 (1.1) <0.001
Number of lung cancer deaths (%) 63 (0.6) 63 (1.0) 0.028 9 (0.1) 17 (0.2) 0.24 72 (0.4) 80 (0.5) 0.142
Number of cancer deaths, excluding
lung cancer (%)
287 (2.9) 313 (4.8) <0.001 117 (1.4) 203 (2.3) <0.001 404 (2.3) 516 (3.3) <0.001
Number of all-cause deaths, excluding
cancer (%)
292 (3.0) 380 (5.8) <0.001 117 (1.4) 212 (2.4) <0.001 409 (2.3) 592 (3.8) <0.001
Figure 2. Cumulative incidence, mortality of lung cancer, and all-cause mortality in both groups. a. Lung cancer incidence, b. Lung cancer mortality, c. All-cause mortality.
Table 3. Hazard ratios for lung cancer incidence, mortality and all-cause mortality according to the pack-years 1 and PYC1 scenarios.
Multivariate analysisa Lung cancer incidence Lung cancer mortality All-cause mortality
Method (ref: XP) HRb 95% C.I.c HR 95% C.I. HR 95% C.I.
CT 1.23 1.00–1.51 0.49 0.34–0.70 0.57 0.52–0.62
Gender (ref: Female)
Male 1.09 0.83–1.45 2.12 1.20–3.76 1.89 1.67–2.13
Age group (ref: 50–55)
56–63 1.91 1.46–2.50 1.62 0.99–2.67 1.80 1.56–2.07
64–74 2.50 1.91–3.26 3.46 2.17–5.52 4.29 3.76–4.90
Pack-years (ref: 0)
0< and <30 1.38 1.02–1.86 1.80 1.04–3.16 1.10 0.98–1.25
30≤ and <50 2.42 1.76–3.32 5.69 3.30–9.80 1.36 1.18–1.58
50≤ 3.63 2.46–5.67 6.57 3.43–12.60 1.70 1.39–2.07
aCox proportional hazards model, bHazard ratio, c95% Confidence interval.
Jpn J Clin Oncol, 2019, Vol. 49, No. 2 133
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and all-cause mortality rate were significantly lower. Regarding the
other factors, the lung cancer incidence rate, lung cancer mortality
rate and all-cause mortality rate increased with age or pack-years
value. The lung cancer mortality rate and all-cause mortality rates
were higher in males than in females.
The hazard ratios of analyses with respect to screening modalities
(LDCT screening/X-ray screening) in the ‘PYC2-4’ scenarios are shown
in Supplementary Table. The incidence of lung cancer, lung cancer mor-
tality rate and all-cause mortality rate ranged from 1.20 to 1.27, 0.46 to
0.52 and 0.57 to 0.58, respectively, and were similar to those in the
‘PYC1’ scenario. In addition, the results of analyses of the ‘PYC1–4’
scenarios of ‘pack-years 2’ were similar. There was no notable difference
between our results and those of the complete case analysis.
The hazard ratios of LDCT screening for the lung cancer incidence
rate, lung cancer mortality rate and all-cause mortality rate in gender-/
age-/pack-year-based subgroups with the ‘pack-years 1’ and ‘PYC1’
scenarios are shown in Fig. 3. As the number of subjects in the sub-
groups was limited, there were no significant differences in most sub-
groups. However, subgroup analyses revealed some differences in
hazard ratios from the overall results, i.e. LDCT screening increased
the lung cancer incidence rate in females (hazard ratio: 2.15) and non-
smokers (1.79) and decreased the lung cancer mortality rate in younger
subjects (0.20 in 50−55 years and 0.35 in 56−63 years) and non-/light
smokers (0.41 in non-smokers, and 0.21 in 0< and <30 pack-years).
Discussion
We reported the results of a cohort study involving residents in
Hitachi city, Ibaraki Prefecture, Japan, where LDCT screening had
been widely conducted for residents for many years. The risk of
lung cancer death for residents who underwent LDCT screening
decreased by 51% and the risk of lung cancer increased by 23% in
comparison with those who underwent X-ray screening. On the
other hand, the risk of all-cause death in the CT group decreased by
43%. This is the first cohort study regarding the effectiveness of
LDCT screening for subjects including non-/light smokers.
Regarding the lung cancer incidence rate, the number of subjects
diagnosed with lung cancer in the CT group was 1.23 times greater
than that in the XP group. The detection capacity of low-dose CT
for lung cancer may be much higher than that of chest X-ray.
Moreover, most lesions detected by LDCT screening in Japan have
been lung cancer measuring ≤20mm in diameter (10–12), most of
which were not detectable by X-ray screening. As indicated in the
graph of the cumulative lung cancer incidence rate (Fig. 2a), more
lung cancers were detected in the CT group than in the XP group
within a follow-up period of ≤2 years, leading to a marked differ-
ence between the two groups. Subsequently, the lung cancer inci-
dence rate increased in the XP group 5−7 years after the first
screening, reducing the difference. This result suggests a delay in the
detection of some lung cancer lesions in the XP group in comparison
with early detection in the CT group. Such changes in the incidence
rate related to the interval after the first screening were similar to
the results of the NLST (7).
Regarding the lung cancer mortality rate, there was no marked
difference between the two groups within 2 years after the first
screening. The cumulative lung cancer mortality rate in the CT group
was lower than that in the XP group after 3–4 years, but the relative
difference decreased 5–8 years after the first screening (Fig. 2b).
Ideally, cancer mortality should not decrease in the early period after
the introduction of cancer screening due to the detection of curative
and advanced cancers, and instead decreases in the later period. TheFi
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timing of lung cancer mortality in our present study was consistent
with this scenario and the results of the NLST (7). Furthermore, the
lung cancer incidence rate in the XP group increased 5−7 years after
the first screening and the lung cancer mortality rate in the XP group
increased during the same period. These results demonstrated that
some lung cancer lesions were detected several years later in the XP
group as advanced cancer. These results are consistent with our previ-
ous chronological study that demonstrated a 24% reduction in the
lung cancer mortality rate among residents in Hitachi city 4−8 years
after the introduction of LDCT screening in comparison with the
lung cancer mortality in Japan (14).
In subgroup analyses, LDCT screening was associated with an
increase in the lung cancer incidence rate in females and non-smokers,
and with a decrease in lung cancer mortality in younger subjects and
non-/light smokers. This increase in the incidence rate is consistent
with the large number of ground-glass nodules with a long doubling-
time observed on LDCT screening in females and non-smokers.
Regarding the lung cancer mortality rate, it should be noted that the
hazard ratios were low even in non-/light smokers, and the possibility
that LDCT screening is ineffective for non-/light smokers, as suggested
in previous reports (17,19), was not indicated in the present study.
For cancer screening, overdiagnosis is always present to some
extent. A previous study found that a maximum of 11.0% of all lung
cancer patients undergoing LDCT screening were overdiagnosed in
the NLST (16). During LDCT screening for non-/light smokers, a
large number of lung cancer lesions with ground-glass nodules with a
long doubling-time were detected (17–19); therefore, some investiga-
tors speculated that overdiagnosis markedly increases for non-/light
smokers. In the present study, 55.1% of the subjects in the CT group
and 67.8% of those in the XP group were non-smokers, and many
lung cancer lesions were small-sized cancers or pure ground-glass
nodules in the CT group (12,15). However, the incidence rate of lung
cancer in the CT group was only 1.23-fold that in the XP group.
When calculating overdiagnosis in accordance with the method
described by Patz et al., a maximum of 18.7% of all lung cancer
patients in the CT group were overdiagnosed. The value was higher
than the 11.0% in the NLST but was lower than expected and not
excessive in comparison with other cancer screening methods (20).
Furthermore, due to the short observation period, it is unclear how
many deaths will be due to lung cancer in the future. Thus, the true
overdiagnosis rate in the CT group may be lower than this value.
In addition to overdiagnosis, the potential harm of LDCT screen-
ing, including radiation exposure, is of concern. In the present study,
the all-cause mortality rate in the CT group was consistently lower
than that in the XP group throughout the observation period from
the beginning of the follow-up period, and the subsequent slopes of
curves for the CT and XP groups were constant (Fig. 2c). This pat-
tern is different from those of the lung cancer mortality rate, sug-
gesting that there is no increase in mortality associated with LDCT
screening. However, side effects due to radiation exposure do not
appear until a long period of time has elapsed; therefore, we cannot
conclude this issue with short-term observation.
There are several limitations in this study that must be discussed.
First, we cannot deny the existence of self-selection bias, because the
hazard ratio of all-cause mortality in the CT group as low as 0.57
cannot be explained with only a reduction in lung cancer mortality
(hazard ratio 0.49). However, the CT group had more heavy smo-
kers than the XP group. In addition, the lung cancer incidence rate
in both groups was similar after the initial CT group distribution, as
shown in Fig. 2b. We considered there to be no significant difference
in the risk of lung cancer between the two groups.
Second, when discussing the effectiveness of cancer screening, the
disadvantages should also be discussed. In this study, disadvantages
other than overdiagnosis, such as false-positive cases, were not directly
investigated, but we previously reported that a low positive rate was
maintained by establishing a protocol for the management of pulmonary
nodules at the start of LDCT screening in Hitachi city in 1998 to avoid
excessively detailed examinations or invasive treatment (12). The disad-
vantages of LDCT screening should be further investigated in the future.
Third, data were complemented with insufficient pack-years data
in this study; therefore, the validity must be confirmed. We con-
ducted the multiple-imputation procedure for sensitivity analysis
(10 imputation datasets were created, with two sets of variables
used for complementation) and the complete case analysis with
deficit-value-free data alone. As a result, the hazard ratios for lung
cancer mortality were 0.49−0.50 using the multiple imputation, and
those for all-cause mortality were 0.57, which were similar to the
results of primary analyses. Based on the results of complete case
analyses, the hazard ratios for lung cancer mortality were 0.45
−0.47, and those of all-cause mortality were 0.57−0.58, which were
also similar to the results of primary analyses. These results con-
firmed the validity of data complementation in primary analyses.
Fourth, the subjects were grouped into either the CT or XP
group according to a screening history during a specified period
without taking the interval from screening to diagnosis into account
in the analyses. Consequently, both groups included subjects with a
long interval from screening to diagnosis, for which the screening
was unlikely to have contributed to the diagnosis of lung cancer.
Therefore, the misclassification of screening status was inevitable in
relation to the timing of the diagnosis of lung cancer.
Fifth, as considerably more lung cancers with a long doubling-time
were assumed to be detected by LDCT screening in non-/light smokers
than in heavy smokers, annual screening may have been excessive and
disadvantageous for the subjects. The NELSON study suggested that
annual LDCT screening was excessive for individuals with negative
findings on the first screening (21). However, there are no reliable data
for an adequate interval, and it was not clarified in this study. To pre-
sent an adequate screening schedule in accordance with individual
risks, a case-control study or model analysis may be helpful.
In conclusion, a cohort study including non-/light smokers with a
mean follow-up of ≥9 years demonstrated that the incidence of lung
cancer in residents in Hitachi city who underwent LDCT screening
increased by 23% in comparison with that in those who underwent
X-ray screening. On the other hand, the lung cancer and all-cause
mortality rates decreased by 51 and 43%, respectively. Thus, lung
cancer screening using low-dose CT for a population including non-/
light smokers may be effective. Furthermore, no deterioration of the
hazard ratio may be important even for subgroup analysis of non-/
light smokers. The effectiveness of lung cancer screening for non-/light
smokers using low-dose CT should be further investigated.
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